Elizabeth G VanDenKerkhof1, Larry Stitt2, Alexander J Clark3, Allan Gordon4, Mary Lynch5, Patricia K Morley-Forster6, Howard J Nathan7, Catherine Smyth7, Cory Toth8, Mark A Ware9, Dwight E Moulin10. 1. Department of Anesthesiology & Perioperative Medicine, School of Nursing, Queens University, Kingston. 2. LW Stitt Statistical Services. 3. Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax. 4. Wasser Pain Management Centre, Mount Sinai Hospital, University of Toronto, Toronto. 5. Anesthesiology, Pain Medicine and Perioperative Care, Psychiatry Pharmacology, Dalhousie University, Halifax, NS. 6. Department of Anesthesia & Perioperative Medicine. 7. Department of Anesthesiology, University of Ottawa, Ottawa, ON. 8. Burnaby Hospital, Burnaby, BC. 9. Department of Family Medicine, McGill University, Montreal, QC, Canada. 10. Department of Clinical Neurological Sciences, Western University, London.
Abstract
OBJECTIVES: Several tools have been developed to screen for neuropathic pain. This study examined the sensitivity of the Douleur Neuropathique en 4 Questions (DN4) in screening for various neuropathic pain syndromes. MATERIALS AND METHODS: This prospective observational study was conducted in 7 Canadian academic pain centers between April 2008 and December 2011. All newly admitted patients (n=2199) were approached and 789 eligible participants form the sample for this analysis. Baseline data included demographics, disability, health-related quality of life, and pain characteristics. Diagnosis of probable or definite neuropathic pain was on the basis of history, neurological examination, and ancillary diagnostic tests. RESULTS: The mean age of study participants was 53.5 years and 54.7% were female; 83% (n=652/789) screened positive on the DN4 (≥4/10). The sensitivity was highest for central neuropathic pain (92.5%, n=74/80) and generalized polyneuropathies (92.1%, n=139/151), and lowest for trigeminal neuralgia (69.2%, n=36/52). After controlling for confounders, the sensitivity of the DN4 remained significantly higher for individuals with generalized polyneuropathies (odds ratio [OR]=4.35; 95% confidence interval [CI]: 2.15, 8.81), central neuropathic pain (OR=3.76; 95% CI: 1.56, 9.07), and multifocal polyneuropathies (OR=1.72; 95% CI: 1.03, 2.85) compared with focal neuropathies. DISCUSSION: The DN4 performed well; however, sensitivity varied by syndrome and the lowest sensitivity was found for trigeminal neuralgia. A positive DN4 was associated with greater pain catastrophizing, disability and anxiety/depression, which may be because of disease severity, and/or these scales may reflect magnification of sensory symptoms and findings. Future research should examine how the DN4 could be refined to improve its sensitivity for specific neuropathic pain conditions.
OBJECTIVES: Several tools have been developed to screen for neuropathic pain. This study examined the sensitivity of the Douleur Neuropathique en 4 Questions (DN4) in screening for various neuropathic pain syndromes. MATERIALS AND METHODS: This prospective observational study was conducted in 7 Canadian academic pain centers between April 2008 and December 2011. All newly admitted patients (n=2199) were approached and 789 eligible participants form the sample for this analysis. Baseline data included demographics, disability, health-related quality of life, and pain characteristics. Diagnosis of probable or definite neuropathic pain was on the basis of history, neurological examination, and ancillary diagnostic tests. RESULTS: The mean age of study participants was 53.5 years and 54.7% were female; 83% (n=652/789) screened positive on the DN4 (≥4/10). The sensitivity was highest for central neuropathic pain (92.5%, n=74/80) and generalized polyneuropathies (92.1%, n=139/151), and lowest for trigeminal neuralgia (69.2%, n=36/52). After controlling for confounders, the sensitivity of the DN4 remained significantly higher for individuals with generalized polyneuropathies (odds ratio [OR]=4.35; 95% confidence interval [CI]: 2.15, 8.81), central neuropathic pain (OR=3.76; 95% CI: 1.56, 9.07), and multifocal polyneuropathies (OR=1.72; 95% CI: 1.03, 2.85) compared with focal neuropathies. DISCUSSION: The DN4 performed well; however, sensitivity varied by syndrome and the lowest sensitivity was found for trigeminal neuralgia. A positive DN4 was associated with greater pain catastrophizing, disability and anxiety/depression, which may be because of disease severity, and/or these scales may reflect magnification of sensory symptoms and findings. Future research should examine how the DN4 could be refined to improve its sensitivity for specific neuropathic pain conditions.
Authors: An De Groef; Nele Devoogdt; Ceren Gursen; Niamh Moloney; Victoria Warpy; Jolien Daelemans; Lore Dams; Vincent Haenen; Elien Van der Gucht; An-Kathleen Heroes; Tessa De Vrieze; Elizabeth Dylke Journal: J Cancer Surviv Date: 2021-08-28 Impact factor: 4.062
Authors: David J Kopsky; Ruben P A van Eijk; Janna K Warendorf; Jan M Keppel Hesselink; Nicolette C Notermans; Alexander F J E Vrancken Journal: Trials Date: 2022-10-22 Impact factor: 2.728
Authors: Mária Földi; Noémi Gede; Szabolcs Kiss; Áron Vincze; Judit Bajor; Imre Szabó; Zoltán Szepes; Ferenc Izbéki; Judit Gervain; József Hamvas; Zsuzsanna Vitális; Eszter Fehér; Stefan Crai; Ville Sallinen; Elena Ramirez-Maldonado; Ágnes Meczker; Péter Varjú; Goran Poropat; Davor Stimac; Nándor Faluhelyi; Attila Miseta; Tamás Nagy; Zsolt Márton; András Vereczkei; Péter Jenő Hegyi; Andrea Párniczky; Péter Hegyi; Andrea Szentesi Journal: Eur J Pain Date: 2021-11-16 Impact factor: 3.651
Authors: Christian Dürsteler; Carlos Cordero-García; Carlos Ignacio García Fernández; Juan V Peralta Molero; Ignacio Morón Merchante Journal: Medicine (Baltimore) Date: 2020-12-24 Impact factor: 1.817